Screener
Seres Therapeutics MCRB Q2 2026 earnings
Reported August 5, 2026 · Before market open
Revenue$736.0KBeat by $557.0K
EPS$0.47Beat by $2.65
Revenue estimate$179.0K
EPS estimate-$2.18
Next report
Nov 4, 2026 (in 2 months)Revenue estimate$6.4M
EPS estimate-$1.01
Versus estimates
Revenue
Q2 2026$736.0KBeat by $557.0K
Q1 2026$358.0KIn lineQ4 2025$438.0KMiss by $4.9MQ3 2025$351.0KMiss by $7.5MDiluted EPS
FAQ
- When did Seres Therapeutics report Q2 2026 earnings?
- Seres Therapeutics (MCRB) reported Q2 2026 earnings on August 5, 2026 before market open.
- What were Seres Therapeutics's Q2 2026 revenue and EPS?
- Seres Therapeutics reported revenue of $736.0K and eps of $0.47 for Q2 2026.
- Did Seres Therapeutics beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $179.0K by $557.0K. EPS beat the consensus estimate of $-2.18 by $2.65.
- Where can I find Seres Therapeutics's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-332742) and the 10-Q periodic report (0001193125-26-334174) directly on SEC EDGAR. The filing index links above go to sec.gov.
